Global Assets Advisory LLC Has $772,000 Position in Eli Lilly and Company (NYSE:LLY)

Global Assets Advisory LLC cut its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 56.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 992 shares of the company's stock after selling 1,293 shares during the period. Global Assets Advisory LLC's holdings in Eli Lilly and Company were worth $772,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Highline Wealth Partners LLC increased its position in shares of Eli Lilly and Company by 80.0% in the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company's stock worth $35,000 after purchasing an additional 20 shares during the period. FPC Investment Advisory Inc. grew its stake in Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock worth $45,000 after purchasing an additional 43 shares during the period. Prudent Man Investment Management Inc. acquired a new position in shares of Eli Lilly and Company during the 4th quarter valued at $48,000. Compass Financial Services Inc acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $50,000. Finally, Fiduciary Advisors Inc. bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at approximately $58,000. Institutional investors and hedge funds own 82.53% of the company's stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. StockNews.com raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Finally, Guggenheim reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $1,002.80.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $20.71 during mid-day trading on Monday, reaching $755.28. The company's stock had a trading volume of 9,154,422 shares, compared to its average volume of 3,540,196. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The business has a 50 day moving average price of $810.98 and a 200-day moving average price of $810.32. Eli Lilly and Company has a twelve month low of $677.09 and a twelve month high of $972.53. The firm has a market cap of $715.80 billion, a price-to-earnings ratio of 64.50, a PEG ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The company had revenue of $12.73 billion for the quarter, compared to the consensus estimate of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 earnings per share. Eli Lilly and Company's revenue for the quarter was up 45.2% compared to the same quarter last year. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be issued a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a dividend yield of 0.79%. Eli Lilly and Company's dividend payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.